Journal ArticleDOI
AS1411 aptamer tagged PLGA-lecithin-PEG nanoparticles for tumor cell targeting and drug delivery.
Athulya Aravind,Prashanti Jeyamohan,Remya Nair,Srivani Veeranarayanan,Yutaka Nagaoka,Yasuhiko Yoshida,Toru Maekawa,D. Sakthi Kumar +7 more
TLDR
Drug‐loading studies indicated that under the same drug loading, the aptamer‐targeted NPs show enhanced cancer killing effect compared to the corresponding non‐targeting NPs, and the PLGA‐lecithin‐PEG NPs exhibited high encapsulation efficiency and superior sustained drug release than the drug loaded in plain PLGA NPs.Abstract:
Liposomes and polymers are widely used drug carriers for controlled release since they offer many advantages like increased treatment effectiveness, reduced toxicity and are of biodegradable nature. In this work, anticancer drug-loaded PLGA-lecithin-PEG nanoparticles (NPs) were synthesized and were functionalized with AS1411 anti-nucleolin aptamers for site-specific targeting against tumor cells which over expresses nucleolin receptors. The particles were characterized by transmission electron microscope (TEM) and X-ray photoelectron spectroscopy (XPS). The drug-loading efficiency, encapsulation efficiency and in vitro drug release studies were conducted using UV spectroscopy. Cytotoxicity studies were carried out in two different cancer cell lines, MCF-7 and GI-1 cells and two different normal cells, L929 cells and HMEC cells. Confocal microscopy and flowcytometry confirmed the cellular uptake of particles and targeted drug delivery. The morphology analysis of the NPs proved that the particles were smooth and spherical in shape with a size ranging from 60 to 110 nm. Drug-loading studies indicated that under the same drug loading, the aptamer-targeted NPs show enhanced cancer killing effect compared to the corresponding non-targeted NPs. In addition, the PLGA-lecithin-PEG NPs exhibited high encapsulation efficiency and superior sustained drug release than the drug loaded in plain PLGA NPs. The results confirmed that AS1411 aptamer-PLGA-lecithin-PEG NPs are potential carrier candidates for differential targeted drug delivery. Biotechnol. Bioeng. 2012; 109: 2920–2931. © 2012 Wiley Periodicals, Inc.read more
Citations
More filters
Journal ArticleDOI
Oligonucleotide Aptamers: New Tools for Targeted Cancer Therapy
TL;DR: The potential applications of aptamer technology as a new tool for targeted cancer therapy with emphasis on the development of aptamers that are able to specifically target cell surface biomarkers are discussed.
Journal ArticleDOI
Aptamers: Problems, Solutions and Prospects
TL;DR: This review is mostly devoted not to the successful use of aptamers but to the problems impeding the widespread application of aptAMers in diagnostics and therapy, as well as to approaches that could considerably expand the range of aptamer application.
Journal ArticleDOI
Aptamers as Therapeutics
TL;DR: A short history of aptamers and SELEX is presented, their pharmacological development and optimization is described, and potential treatment of diseases including visual disorders, thrombosis, and cancer is reviewed.
Journal ArticleDOI
A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma.
Jonathan E. Rosenberg,Jonathan E. Rosenberg,Richard Martin Bambury,Eliezer M. Van Allen,Eliezer M. Van Allen,Harry A. Drabkin,Primo N. Lara,Andrea L. Harzstark,Nikhil Wagle,Robert A. Figlin,Gregory W. Smith,Levi A. Garraway,Toni K. Choueiri,Fredrik Erlandsson,Damian A. Laber +14 more
TL;DR: AS1411 appears to have minimal activity in unselected patients with metastatic RCC, however, rare, dramatic and durable responses can be observed and toxicity is low.
Journal ArticleDOI
Nanotechnology-based approaches in anticancer research
Nasimudeen R. Jabir,Shams Tabrez,Ghulam Md Ashraf,Shazi Shakil,Ghazi A. Damanhouri,Mohammad Amjad Kamal +5 more
TL;DR: The present review summarizes the application of various nanotechnology-based approaches towards the diagnostics and therapeutics of cancer.
References
More filters
Journal ArticleDOI
Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer
William J. Gradishar,Sergei Tjulandin,Neville Davidson,Heather S. Shaw,Neil Desai,P. Bhar,Michael M. Hawkins,Joyce O'Shaughnessy +7 more
TL;DR: The improved therapeutic index and elimination of corticosteroid premedication required for solvent-based taxanes make the novel albumin-bound paclitaxel ABI-007 an important advance in the treatment of MBC.
Journal ArticleDOI
Endocytosis of Nanomedicines
TL;DR: This review describes the current experimental tools to study endocytosis of nanomedicines and provides specific examples from recent literature and the authors' own work on endocyTosis of Nanomedicine.
Journal ArticleDOI
Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer.
TL;DR: Current knowledge on liposome and nanoparticles offer increased precision in chemotherapeutic targeting of prostate cancer and new avenues for the treatment of breast cancer are reviewed.
Journal ArticleDOI
Self-assembled lipid--polymer hybrid nanoparticles: a robust drug delivery platform.
Liangfang Zhang,Juliana M. Chan,Frank X. Gu,June-Wha Rhee,Andrew Z. Wang,Andrew Z. Wang,Aleksandar Filip Radovic-Moreno,Frank Alexis,Frank Alexis,Robert Langer,Omid C. Farokhzad +10 more
TL;DR: The engineering of a novel lipid-polymer hybrid nanoparticle (NP) as a robust drug delivery platform, with high drug encapsulation yield, tunable and sustained drug release profile, excellent serum stability, and potential for differential targeting of cells or tissues is reported.
Journal ArticleDOI
Discovery and Development of the G-rich Oligonucleotide AS1411 as a Novel Treatment for Cancer
TL;DR: The serendipitous discovery of the G-rich oligonucleotides led to the identification of nucleolin as a new molecular target for cancer therapy, and this molecule functions as an aptamer to nucleolin, a multifunctional protein that is highly expressed by cancer cells, both intracellularly and on the cell surface.